Lung cancer is the most common cancer as evident from a comprehensive global report that also showed ∼1.8 million new cases reported in 2012[@b1]. It has been one of the leading causes of cancer-related mortality worldwide (19.4% of all cancers). Additionally, it is more prominent in developing countries (58%) than in developed countries[@b1]. The abnormal activation of epidermal growth factor receptor (EGFR) tyrosine kinase is responsible for promoting various tumor types, including lung cancer and breast cancer either via an increase in the levels of extracellular ligand, hetero-dimerization of EGFR or its mutational activation[@b2][@b3]. The most common EGFR mutations reported so far in the case of non-small cell lung cancer (NSCLC) are the deletion of exon 19 and substitution mutation (L858R) at exon 21, leading to constitutive tyrosine kinase activity independent of ligand binding[@b4].

Considering the role of EGFR in tumor progression, targeting it for NSCLC treatment is an effective approach. In this direction, various small molecule tyrosine kinase inhibitors, such as erlotinib, gefitinib, lapatinib have been developed and are being used as US Food and Drug Administration (FDA) approved drugs in breast cancer and NSCLC treatment regime[@b5]. Gefitinib has emerged as a novel therapeutic molecule impairing the tyrosine kinase activity of EGFR effectively. This impairment leads to blockage of downstream signaling and thus inhibits the tumor proliferation activity of EGFR[@b6][@b7][@b8]. This drug is administered orally at a dosage of 250--500 mg/day and is implemented as first-, second- and third -line therapy in cases of NSCLC[@b9].

Gefitinib has certain side effects such as nausea, vomiting, diarrhea and interstitial lung disease[@b10]. These adverse side effects may be accounted by inhibition of either EGFR and/or drug off-targets[@b11]. Therefore, analyzing the off-targets of this drug will prove to be effective to reveal the true scenario of Gefitinib: aids and ills and will help in rational modifications of this drug to minimize the side effects. Additionally, for successful establishment of highly efficient drug-based therapies, early identification of adverse drug effects can be a crucial step as up to 40% of drug failures occur during development, adverse events in pre-clinical trials and pharmacokinetics[@b12].

Identification of drug off-targets by an *in vitro* counter screening of compounds against numerous receptors and enzymes is expensive and time-consuming[@b13][@b14]. In contrast, *in silico* analysis of drug off-targets is safe, time-efficient, economical and provides a deeper understanding of the molecular mechanisms of protein-drug interactions. It has been shown that based on the establishment of the structure-activity relationship of small molecules, an *in silico* off-target identification can be obtained[@b15][@b16]. Various structure-based tools for comparing binding sites of small ligands of distantly related proteins have been developed[@b17].

In the present study, we identified gefitinib off-targets using structure-based systems biology approach. We could confirm the binding of identified off-targets with gefitinib using a reverse docking approach. Additionally, through comparative re-docking analyses of identified off-targets with their respective experimentally characterised ligands (ligands that were present in the crystal structure of the protein) and gefitinib, we observed that a few identified off-targets may bind more efficiently with gefitinib compared to their previously reported and experimentally validated ligands. Furthermore, literature survey and data mining has clearly shown several of the identified off-targets were validated in previously reported *in vitro* studies. Together, these observations clearly suggest that off-targets of gefitinib identified in this study might be true off targets and could be involved in the molecular mechanism underlying the possible side effects of this drug. Interestingly, our study suggested not only negative side effects but also positive roles of gefitinib. Additionally, we could identify non-human off-targets that may be used for effective treatment of pathogen-based diseases.

Results
=======

Prediction of gefitinib off-targets through Molecular interaction field (MIF) similarity search
-----------------------------------------------------------------------------------------------

To carry out the molecular interaction fields (MIFs) similarity search, the crystal structure of EGFR kinase with gefitinib (PDB id: 4WKQ) was used as query structure. This structure showed the binding of different molecules; viz., gefitinib (IRE), 2-(N-morpholino)-Ethanesulfonic acid and sodium ion in the native state. The binding pocket of EGFR kinase around the gefitinib was calculated at the distance of 3 Å and it was found to be defined by residues Leu718, Gly719, Ala743, Ile744, Lys745, Glu762, Met766, Leu788, Thr790, Gln791, Leu792, Met793, Pro794, Phe795, Gly796, Arg841, Asn842, Leu844, Thr854, Asp855 and Phe856 ([Fig. 1A,B](#f1){ref-type="fig"}). Gefitinib interacts with Met793 in the EGFR binding pocket via H-bond formation with the nitrogen atom of the quinazoline ring and Van der Waals interactions.

The MIFs of ligand binding cavities of proteins listed in sc-PDB database (containing 8077 protein structures) were calculated using six properties; H-bond donor/acceptor, aromatic, hydrophobic and positively/negatively charged interactions and compared with query MIF (i.e. Gefitinib binding pocket of EGFR). All the analyzed protein structures were ranked and arranged according to the Tanimoto scores (designated as MIF ranking; [Supplementary Table S1](#S1){ref-type="supplementary-material"}). In total, 128 protein structures were found to have Tanimoto scores of ≥0.35 value. These were considered as putative off-targets of Gefitinib, and were selected for further analysis. These selected protein structures represent 50 proteins ([Table 1](#t1){ref-type="table"}). These hits belong to following species; human (41), rat (3), *Xenopus laevis*, *Pseudomonas putida, Toxoplasma gondii, Cryptosporidium parvum, E. coli*, *Betula pendula* and *Zea mays* (1 each). For subsequent analysis, we focused on the 41 identified-human proteins ([Table 1](#t1){ref-type="table"}). Most of the putative off-target hits (107) belong to protein kinase family (pfam ID: PF00069 and PF07714). The remaining hits belong to pfam domain Ephrin type-A receptor 2 transmembrane domain, EF-hand domain, Cartilage oligomeric matrix protein, transforming growth factor beta type I GS-motif, MAATS-type transcriptional repressor, Dihydroorotate dehydrogenase, Protein Kinase C terminal domain etc. The pfam ids of above domains are listed in [Table 1](#t1){ref-type="table"}. Furthermore, the known functions and subcellular localization of the selected proteins are shown in [Table 1](#t1){ref-type="table"}.

As anticipated, the top ranked structure in MIF search analysis was found to be that of mutated EGFR kinase domain (G719S/T790M) in complex with gefitinib. This data indicates that the method used for binding pocket similarity analysis is appropriate and quite accurate. The other top-ranked structures such as Serine/threonine-protein kinase Chk1 (CHEK1; MIF ranked 2) in complex with 3-(Indol-2-yl) indazoles and Mitogen activated protein kinase-14 (MAPK14; MIF ranked 3) bound with an inhibitor 4-\[3-methylsulfanylanilino\]-6,7-dimethoxyquinazoline (PDB IDs: 2HOG and 1DI9, respectively) show high similarity to EGFR binding site and might the true off-target proteins.

The superimposed structures obtained from the detailed MIF analysis of query (EGFR) and top ranked off-targets (CHEK1 and MAPK14) are shown for five probes (color spheres; [Fig. 2](#f2){ref-type="fig"}). The probes of query and off-target proteins are shown by bigger and smaller spheres, respectively. There are abundant hydrophobic probes surrounding ligands of both query protein and off-targets (cyan spheres in [Fig. 2A](#f2){ref-type="fig"},B). H-donor probes (blue sphere) of query and off-targets surround the nitrogen (N)-containing C-rings of the ligands. In case of MAPK14, H-donor residues surrounded O-31 and N-containing C-ring same as N-containing C-rings and F present in side group in gefitinib. Positive and negative probes (green and magenta spheres, respectively) surround N-containing C-ring and S-21 containing C-ring in CHEK1 and MAPK14 bound ligands respectively. This indicates that binding pockets of EGFR and the identified off-targets are very similar in nature and therefore it could be argued that gefitinib might be able to bind with these off-targets efficiently and modulate their functions.

Identification and characterization of binding pockets of off-targets
---------------------------------------------------------------------

For binding pocket estimation, we considered only pocket in which the ligand of respective off-target protein was bound. We defined the pocket at the threshold distance of 4 Å based on ligand proximity that is limited to short interactions. The defined pocket with a score ≥0.5 was considered as highly druggable pocket. After estimation of pockets in 128 off-targets, 120 pockets were found to have druggable probability greater than 0.5. Only 8 pockets had values of less than 0.5 ([Supplementary Table S2](#S1){ref-type="supplementary-material"}). Since all the identified-pockets were from the crystal structure and have at least one bound ligand, the predicated druggability value of less than 0.5 could not be ignored. The PockDrug server also calculated 66 physicochemical properties (such as hydrophobicity, polarity, aromaticity etc.) of the pockets and the selected parameters are shown in [Supplementary Table S2](#S1){ref-type="supplementary-material"}. The binding pocket volumes ranged from 257.99 to 1766.88.

*In silico* confirmation of off-targets using ligand-protein docking
--------------------------------------------------------------------

To further investigate the off-targets identified through MIF similarity searches, we used a reverse docking approach. The docking of gefitinib with each of 128 off-target structures was performed. The docking score was calculated for each gefitinib binding pose that ranges from −1.224 to −12.025, and was subjected to local refinement, binding energy calculations (MM-GBSA method). The 128 structures were re-ranked according to the MM-GBSA binding energy (G-rank; according to lowest binding energies; [Supplementary Table S3](#S1){ref-type="supplementary-material"}). Notably, the mutant EGFR kinase domain bound with gefitinib (G179S/T790M; PDB id 3UG2), that was ranked first in MIF similarity search, also showed efficient docking score and binding energy (−6.818 and −77.11 kcal/mol, respectively). The ligand interacts with Met793 and Asp800 via H-bond and Glu791 residues via polar contacts ([Fig. 3A](#f3){ref-type="fig"}). Seven human off-targets (i.e. MAPK10, PIM-1, DHODH, ERBB-4, HSD17B1, CHK2, CHK1) were found to bind with gefitinib with equal or better binding energy than EGFR ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). The binding energy for these off-target ranges from −103.446 to −94.712 kcal/mol. The residues involved in binding of gefitinib with these off-targets are shown in [Fig. 3B--H](#f3){ref-type="fig"}.

Comparison of binding efficiency of identified off- targets with gefitinib and reported ligands
-----------------------------------------------------------------------------------------------

To compare and verify the data, we also performed reversed docking of identified off-targets with their previously reported ligands that were already present in the crystal structure of the off-targets. The docking score and binding energies of these bound ligands are shown in [Supplementary Table S3](#S1){ref-type="supplementary-material"}. For determining the difference in binding efficiency of gefitinib ((∆G~gef~) and the respective bound ligand (∆G~lig~) with the off-target structures, the ratio of binding energies (∆G~gef~/∆G~lig~) was calculated and plotted against average binding energies ([Fig. 4](#f4){ref-type="fig"}). The off-targets having ∆G~gef~/∆G~lig~ value ≥ 1.5 were considered to be having significant binding efficiency towards gefitinib compared to their respective reported ligand ([Fig. 4](#f4){ref-type="fig"}, red spheres). In contrast to the bound ligand, gefitinib showed more efficient binding with 15 human and 1 non-human off-target structures ([Fig. 4](#f4){ref-type="fig"}; [Table 2](#t2){ref-type="table"}). This observation is in agreement with various *in vitro* studies that have reported ligands present in the co-crystals of some of these off-target structures had less efficient binding (IC~50~) compared to other inhibitors used in respective *in vitro* studies ([Table 2](#t2){ref-type="table"}). This indicates that gefitinib might also be a potent inhibitor of the identified off-targets.

Retrospective studies of identified off-targets
-----------------------------------------------

Various studies have been published on the comprehensive analysis of kinase inhibitors including gefitinib for their selectivity[@b18][@b19]. The quantitative inhibition data for gefitinib were extracted from previous studies as well as the curated databases DSigDB and ChEMBL[@b18][@b19][@b20][@b21]. These data were compared with the data obtained from the present study. The results from the above comparison validated the proteins ERBB4, PIM1, MAPK10, MAPK14, ALK, LCK, BTK, ABL1, SRC, STK10, TNK2, KIT, IGF1R, SLK, CHK2, MET, STK17B and SYK as true off-targets of gefitinib ([Table 3](#t3){ref-type="table"}). These data confirm the specificity of the *in silico* prediction of gefitinib off-targets. Additionally, we also found DHOH, HSD17B1, BMPR1B, NTRK1, ACVRL1, and TTK and proteins as new off-targets of gefitinib that were not included in previous reports ([Table 3](#t3){ref-type="table"}). Furthermore, we curated the published quantitative inhibition data to identify other off-targets. In total, 22 off-targets that were identified in previous *in vitro* studies however were not found among top 128 hits in our study ([Supplementary Table S4](#S1){ref-type="supplementary-material"}). These proteins were also included for further analysis to assess the effects of gefitinib on molecular pathways and diseases.

Biological pathways analysis
----------------------------

Biological processes were predicted on the basis of gene ontology and the pathways were ranked according to the p-value calculated using Genomatrix software. In total, 971 pathways were found to be significantly correlated with the input off-target genes ([Supplementary Table S5](#S1){ref-type="supplementary-material"}). During this analysis, cellular processes such as protein phosphorylation and related pathways were detected in top 50 hits. The cellular proliferation pathways such as cell growth and apoptosis were strongly associated with gefitinib off-targets. Other biological processes, such as cell differentiation, cell communication, stress response, developmental and metabolic process were also found as top hits according to the p-value. The signaling pathways such as MAPK cascade, immune-response-regulating signalling pathway, serine/threonine kinase pathways and neurotrophin TRK receptor signalling pathway were the major pathways that could be correlated with the major reported side effects ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"})[@b22].

Associated disease analysis
---------------------------

Clinical diseases prediction is crucial to explain the clinical outcome of the side effects of gefitinib. Sixty clinical diseases were predicted using Genomatrix curated database that were significantly correlated with the gefitinib off-target proteins ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). These diseases were group in following broad categories: (i) different cancer types (ii) blood disorders, (iii) bone diseases and (iv) reproductive disorders ([Fig. 5](#f5){ref-type="fig"}). Other discrete diseases/abnormalities of pituitary, endocrine system, hypothalamic, gastrointestinal and bone-marrow were also predicted. These results suggest that gefitinib might have side effects that play a major role in above mentioned diseases.

Discussion
==========

In the present study, we have carried out a comprehensive analysis of gefitinib off-targets using a systems biology approach; most of the identified off-targets could be validated by retrospective analysis of previously reported studies. In addition, we could also identify a few new off-targets such as DHODH, BMPR1B, NTRK1 and HSD17B1. Together, these observations could be useful for defining the molecular basis of gefitinib-induced side effects and might help in rational improvement of the drug for better treatment.

In our analysis, the mutant EGFR kinase domain in complex with gefitinib interacts with gefitinib through the use of the same residues as the wild type EGFR. Characteristically, the wild type EGFR complexed with an imidazo\[2,1-b\]thiazole inhibitor (PDBID 3LZB) also showed efficient binding energy with gefitinib. However, the interacting residues were found to be different and had the lowest binding energy. This suggests that the pocket of EGFR kinase domain may adapt to different conformations for interaction with gefitinib.

Interestingly, the top ranked off-targets showed highest binding site similarity but not efficient binding energy. For example, the EGFR to gefitinib docking shows binding energy −88.354 kcal/mol and gefitinib acts as a strong EGFR inhibitor (∼97% inhibition; Ki 0.4 nM ([Table 3](#t3){ref-type="table"}). Another off-target ERBB4 showed the maximum affinity with gefitinib but was found to be lower ranked in MIF analyses. Notably, ERBB4 is efficiently inhibited by gefitinib (∼76% inhibition; Kd 410 nM) ([Table 3](#t3){ref-type="table"}). Additionally, other proteins e.g. DHODH and BMPR1B etc. (that were not reported in previous *in vitro* analyses) also showed efficient binding energy with gefitinib. These observations suggest that reverse docking might be a suitable approach for confirming the binding affinities. Previously, it has also been shown that the binding energy calculated on docked poses was useful for predicting the binding affinity of the ligand to the receptor[@b23].

During our analyses, a few non-humans off-targets such as src (*Gallus gallus domesticus*), ttgr (*Pseudomonas putida*), aurkb-a (*Xenopus laevis*), ack2 (*Zea mays*), cdpk1 (*Toxoplasma gondii/Cryptosporidium parvum*) and erk2 (*Rattus rattus*) were also found to exhibit efficient binding energy with gefitinib. Amongst the non-human off-targets, ttgr (PDB id: 2UXH), a helix turn helix type transcriptional regulator and antibiotic binding repressor of *Pseudomonas putida* was found to exhibit highly efficient binding with gefitinib (binding energy −100.838 kcal/mol). This observation suggests that gefitinib could be used in potential combination therapy for treatment of antibiotic resistant strains of *Pseudomonas putida*.

Previously reported *in vitro, in vivo* and clinical studies have suggested that gefitinib may induce side effects like pro-apoptosis and cell-cycle inhibition possibly via interacting with off-targets[@b24]. A recent study has demonstrated that gefitinib is able to induce cardiac hypertrophy through differential expression of apoptotic and oxidative stress genes[@b25]. In contrast, a few previous studies have also demonstrated positive effects of gefitinib such as bone pain relief during bone metastasis and brain metastasis[@b26][@b27][@b28]. However, the underline molecular basis of such effects is poorly understood. In the present study, we identified that gefitinib off-targets are associated with different biological pathways that may explain the molecular mechanism of such positive and negative effects of gefitinib. The identified off-targets (ACVR1, DHODH, BTK, FGFR1, EGFR, FGFR2 and CHEK2) are linked with bone diseases. Similarly, an earlier report demonstrating drug resistance against EGFR therapy in rectal diseases and non-small cell lung cancer through dysregulation of EGFR endocytosis can be explained via identified off-targets (LYN, SRC, ABL2, ABL1, SYK, TNK2, MAPKAPK2, GAK and MAPK1) that are involved in endocytosis process.

This study has found the off-targets binding to gefitinib suggesting the molecular mechanisms of the side-effects of this drug. The biological processes, regulated by off-targets are interesting to focus in future studies. Notably, this study also suggested positive roles of gefitinib in the treatment regime. System-wide *in silico* approaches may facilitate the identification of side effects of preclinical and commercial drugs onto the target and off-targets. This strategy may have important applications for rational improvement of drug design and development.

Methods
=======

Druggable proteome data set
---------------------------

Sc-PDB database v.2013 (<http://cheminfo.u-strasbg.fr/scPDB/>) was used as source of druggable proteome for off-target analysis. The data set contains 8077 structures with druggable binding sites that represent 3678 proteins and 5608 different HET ligands[@b29].

Binding site similarity search
------------------------------

To compare physicochemical similarities in binding pockets of different proteins, MIF within binding sites' volumes and pairwise MIF similarities between binding sites were calculated using the IsoMIF Finder (<http://bcb.med.usherbrooke.ca/isomif>)[@b30]. In this study, the crystal structure of EGFR kinase with Gefitinib (PDB id 4WKQ; 1.85 Å) was selected as query protein. The binding pocket at the distance of 3 Å around gefitinib was cropped using GetCleft tool[@b30] and subsequently used for MIF similarities search against Sc-PDB database. The parameters used for analysis were as follows: grid spacing 1.5 Å and geometric distance threshold 3.0 Å. Structures were ranked by Tanimoto score and designated as MIF rank. Top 128 hits of gefitinib binding targets were selected for further studies. The details of 128 PDB structures with references were listed in [Supplementary Table S8](#S1){ref-type="supplementary-material"}.

Pocket estimation and characterization
--------------------------------------

The pockets of top 128 hits were estimated based on ligand proximity within a fixed distance threshold from the bound ligand. To extract the residues localized within threshold distance; "PockDrug-Server" (<http://pockdrug.rpbs.univ-paris-diderot.fr>) was used. The PDB files were uploaded on the server and "prox" method was selected to estimate the pocket using threshold distance at 4 Å. The ligand information in HET code was also given during prediction[@b31].

Protein-Ligand docking
----------------------

The potential off-targets-identified from MIF similarity search were further processed for binding analysis of gefitinib and previously characterized respective ligands. The Glide 6.9 ligand-receptor docking program (Schrödinger 10.4; Schrödinger Inc, USA) was used for docking of gefitinib to each off-target structure. The ligand library of gefitinib was prepared by LigPrep tool from Schrödinger program with OPLS-2005 force field. Receptor grid was generated in the vicinity of bound ligand of each identified-off target crystal structure using Glide-Receptor Grid generation tool with default parameters. Ligand docking was performed with extra precision (XP) Glide docking module. The binding energies of docking poses were calculated using MM-GBSA method (Prime, Schrödinger Inc, USA) with default parameters.

Literature mining and retrospective studies
-------------------------------------------

PubMed and Google Scholar were used to search publications and research studies relevant to gefitinib. These reports were analyzed for determining the selectivity of gefitinib. We also searched DSigDB database, a collection of small molecules including drugs based compounds and their quantitative inhibition data, for the analysis of gefitinib inhibition[@b32].

To analyze the biological pathways corresponding to identified off-targets, Genomatrix software (Genomatrix, Munich, Germany) with Gene Ranker and GePS (Pathway system) modules were used. The identified off-targets were used as input query, network pathways were constructed and the identified pathways were ranked according to p-value.
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![Identification of the Gefitinib binding pocket in EGFR kinase domain.\
(**A**) Schematic illustration of EGFR receptor on the cell membrane. **(B**) The gefitinib binding pocket was calculated at the distance of 3 Å using Maestro. The identified ligand binding pocket is shown in 2D. Residues are colored according to their properties (red, negatively charged; blue, positively charged; cyan, polar; green, hydrophobic; and white, neutral). The H-bond is shown with magenta arrow.](srep33949-f1){#f1}

![Binding site structure similarity between query protein and off-targets CHEK1 and MAPK14.\
The superimposed structures of query and off-target proteins in complex with respective ligands are shown (**A,B**; top, left panel). The similarity of binding pockets in query (green) and off-targets (cyan) are shown (**A,B**; top, right panel). The hydrophobic, donor, acceptor, negative and positive binding site probes are shown separately and are represented by cyan, blue, red, magenta and green colored spheres, respectively (**A,B**; middle and lower panel). Large spheres represent the query binding probe while smaller ones represent the off-targets binding probe.](srep33949-f2){#f2}

![Molecular interactions of gefitinib with selected human off-targets; (**A**) mutant EGFR kinase domain; (**B**) PIM- 1, (**C**) MAPK10; (**D**) CHEK1; (**E**) DHODH; (**F**) ERBB4; (**G**) CHK2 and (**H**) HSD17B1. PDB codes are shown in brackets. The H-bond and polar interactions are represented by black line and green lines respectively.](srep33949-f3){#f3}

![Comparison of the binding energies of gefitinib (∆G~gef~) and the respective bound ligand (∆G~lig~) with the off-target structures.\
The ratio of gefitinib and reported ligand binding energies (∆G~gef~/∆G~lig~) were plotted against the average binding energy of both. The dotted line shows the threshold ratio 1.5. The spheres with read colour show the significant ratio above the threshold value.](srep33949-f4){#f4}

![Prediction of clinical diseases that might be modulated by gefitinib-induced side effects.](srep33949-f5){#f5}

###### The details of off-targets of gefitinib identified through MIF similarity serach analysis.

   S. No.                       Gene names                                                                                PDB ID                                                           UniprotKB ID             Pfam ID                                     Organism                            Functions                                                                                                                          Locations
  -------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------- --------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
     1                            BMPR1B                                                                                   3MDY                                                               O00238                PF08515                                       Human                             positive regulation of chondrocyte differentiation                                                                                 cell membrane
     2                           SRC SRC1                                                                      1YOL, 1Y57 3EN5, 3EN7, 3EN4                                                 P12931 P00523            PF07714                                   Human Chicken                         regulation of cytoskeletal organization, activation of EGF-mediated calcium- chloride channel                                      cell membrane, mitochondrial inner membrane, nucleus, cytoplasm
     3                      FGFR2 BEK KGFR KSAM                                                                         3RI1, 1OEC                                                            P21802                PF07714                                       Human                             regulates the cell proliferation, differentiation, migration, apoptosis, and embryonic development                                 cell membrane, Golgi apparatus, cytoplasmic vesicles
     4                      ACVRL1 ACVRLK1 ALK1                                                                            3MY0                                                               P37023                PF08515                                       Human                             regulator of normal blood vessel development                                                                                       cell membrane
     5                 MAPK8 JNK1 PRKM8 SAPK1 SAPK1C                                                                       3ELJ                                                               P45983                PF00069                                       Human                             regulates the circadian clock                                                                                                      cytoplasm, nucleus
     6                              ALK                                                                                    2XBA                                                               Q9UM73               ALK_HUMAN                                      Human                             genesis and differentiation of the nervous system                                                                                  cell membrane
     7                             Comp                                                                                    1FBM                                                               P35444               COMP_RAT                                        Rat                              regulates structural integrity of cartilage                                                                                        extra cellular matrix
     8      AURKA AIK AIRK1 ARK1 AURA AYK1 BTAK IAK1 STK15 STK6                                                         3LAU, 3UOH                                                            O14965                PF00069                                       Human                             regulates cell cycle progression                                                                                                   cytoplasm, cytoskeleton, microtubule organizing center, centrosome
     9                        DMPK DM1PK MDPK                                                                              2VD5                                                               Q09013              DMPK_HUMAN                                      Human                             maintains skeletal muscle structure and function                                                                                   cell membrane, ER membrane, mitochondrial outer membrane
     10                      SLK KIAA0204 STK2                                                                             2J51                                                               Q9H2G2                PF00069                                       Human                             mediates apoptosis and actin stress fiber dissolution                                                                              cytoplasm
     11                         ERBB4 HER4                                                                                 2R4B                                                               Q15303                PF07714                                       Human                             regulates development of the heart, the central nervous system and the mammary gland, promote apoptosis                            cell membrane, nucleus and mitochondria
     12                        ttgR T1E_0244                                                                               2UXH                                                               Q9AIU0              TTGR_PSEPT                      *Pseudomonas putida* (strain DOT-T1E)             responsible for antibiotics resistance                                                                                             not known
     13                          TNK2 ACK1                                                                                 3EQR                                                               Q07912              ACK1_HUMAN                                      Human                             involved in trafficking and clathrin-mediated endocytosis                                                                          cell membrane, nucleus, endosome
     14                    EGFR ERBB ERBB1 HER1                                                                         3UG2, 3LZB                                                            P00533              EGFR_HUMAN                                      Human                             activates several signal cascades                                                                                                  cell membrane, ER membrane nucleus membrane, Golgi membrane, endosome
     15                       STK25 SOK1 YSK1                                                                              2XIK                                                               O00506              STK25_HUMAN                                     Human                             response against environmental stress                                                                                              cytoplasm, Golgi apparatus
     16                             LCK                                                                  3KMM, 3KXZ, 3ACK, 3MPM, 3AC3, 3AC2, 3AD4                                             P06239               LCK_HUMAN                                      Human                             responsible for selection and maturation of developing T-cells                                                                     cytoplasm, cell membrane
     17                            IGF1R                                                                                   2ZM3                                                               P08069              IGF1R_HUMAN                                     Human                             involved in cell growth and survival control                                                                                       cell membrane
     18                         CHEK1 CHK1                        2HOG, 2E9N, 4FTI, 4FSR, 2XF0, 2HXL, 4FTQ, 2HY0, 4FT3, 4FTN, 2BRB, 2BRH, 2XEY, 4FTO, 2QHM, 2E9U, 4FT0, 3UN9, 4FTC, 2BR1      O14757              CHK1_HUMAN                                      Human                             required for cell cycle arrest and activation of DNA repair                                                                        nucleus, cytoplasm
     19                       PRKCI DXS1179E                                                                               1ZRZ                                                               P41743              KPCI_HUMAN                                      Human                             Plays a protective role against apoptotic stimuli                                                                                  cytoplasm, membrane, nucleus, endosome
     20                      MAP3K9 MLK1 PRKE1                                                                             3DTC                                                               P80192              M3K9_HUMAN                                      Human                             role in the cascades of cellular responses                                                                                         intracellular
     21            FGFR1 BFGFR CEK FGFBR FLG FLT2 HBGFR                                                                 3TT0, 4F64                                                            P11362              FGFR1_HUMAN                                     Human                             essential for regulation of embryonic development, cell proliferation, differentiation and migration                               cytoplasm, cell membrane, nucleus, cytoplasmic vesicles
     22          MAPK14 CSBP CSBP1 CSBP2 CSPB1 MXI2 SAPK2A                                      1DI9, 3FLW, 3KF7, 3ROC, 3IW7, 3FLZ, 3MVM, 2ZB1, 2RG6, 1WBW                                    Q16539              MK14_HUMAN                                      Human                             essential component of the MAP kinase signal transduction pathways responsible for activating the cascades of cellular responses   cytoplasm. nucleus
     23                          KIT SCFR                                                                                  3G0E                                                               P10721               KIT_HUMAN                                      Human                             responsible for regulation of hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, and in melanogenesis     cytoplasm, cell membrane
     24                        STK17B DRAK2                                                                                3LM0                                                               O94768              ST17B_HUMAN                                     Human                             positive regulator of apoptosis                                                                                                    cell membrane, nucleus
     25                       aurkb-a airk2-a                                                                              2VRX                                                               Q6DE08              AUKBA_XENLA                               *Xenopus laevis*                        key regulator of mitosis                                                                                                           nucleus, chromosomes
     26                            ACK2                                                                                    1ZOH                                                               P28523              CSK2A_MAIZE                              *Zea mays* (Maize)                       utilizes acidic proteins                                                                                                           not known
     27                        ABL1 ABL JTK7                                                                        3UE4, 3KF4 (Mouse)                                                        P00519              ABL1_HUMAN                                      Human                             responsible for cell growth and survival                                                                                           cytoplasm, nucleus, mitochondria
     28               MAPK10 JNK3 JNK3A PRKM10 SAPK1B                                                       2O2U, 4Z9L, 3CGO, 2O0U, 3TTJ, 2ZDT                                                P53779              MK10_HUMAN                                      Human                             involved in neuronal proliferation, differentiation, migration and programmed cell death                                           cytoplasm. nucleus, mitochondria, membrane
     29                          MAPKAPK2                                                                                  3KA0                                                               P49137              MAPK2_HUMAN                                     Human                             involved in cytokine production, endocytosis, reorganization of the cytoskeleton, chromatin remodeling and DNA damage response     cytoplasm, nucleus
     30                      BTK AGMX1 ATK BPK                                                                       3PJ1, 3PJ2, 3OCT                                                         Q06187               BTK_HUMAN                                      Human                             Vital for B lymphocyte development, differentiation and signaling                                                                  cytoplasm. nucleus, cell membrane
     31                        ACVR1 ACVRLK2                                                                            3MTF, 3OOM                                                            Q04771              ACVR1_HUMAN                                     Human                             involved for left-right pattern formation during embryogenesis                                                                     membrane
     32                             SYK                                                                                    1XBC                                                               P43405              KSYK_HUMAN                                      Human                             regulates innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development         cytoplasm, cell membrane
     33                    EPHB4 HTK MYK1 TYRO11                                                               2VX1, 2VWU, 2×9F, 2VWX, 2VWW                                                   P54760              EPHB4_HUMAN                                     Human                             important in tumor angiogenesis                                                                                                    cell membrane
     34                            CDPK1                                                                          3T3U, 3NYV, 3MWU, 3MA6                                                   Q9BJF5A3FQ16    Q9BJF5_TOXGO A3FQ16_CRYPI   *Toxoplasma gondii Cryptosporidium parvum* (strain Iowa II)  binds with metals and nucleotides                                                                                                  not known
     35                         CDK6 CDKN6                                                                                 3NUX                                                               Q00534              CDK6_HUMAN                                      Human                             controls cell cycle and differentiation                                                                                            cytoplasm. nucleus
     36                            DHODH                                                                                   3F1Q                                                               Q02127              PYRD_HUMAN                                      Human                             catalyzes the conversion of dihydroorotate to orotate                                                                              mitochondrial inner membrane
     37                         CDK2 CDKN2                                                      3EZV, 2UZD, 2IW6, 3R6X, 1DI8, 2VTQ, 2VU3, 2W17, 3R1Q, 1GIJ                                    P24941              CDK2_HUMAN                                      Human                             control of the cell cycle; essential for meiosis, but non-essential for mitosis                                                    cytoplasm. nucleus, endosome
     38                            PIM1                                                            3MA3, 2O65, 3R04, 3T9I, 3VBY, 3UMX, 4ENY, 3CY3, 3JY0                                       P11309              PIM1_HUMAN                                      Human                             involved in cell survival and cell proliferation, provide advantage in tumorigenesis                                               cytoplasm. nucleus, cell membrane
     39                          STK10 LOK                                                                                 4BC6                                                               O94804              STK10_HUMAN                                     Human                             regulates lymphocyte migration                                                                                                     cell membrane
     40                    Mapk1 Erk2 Mapk Prkm1                                                                           2Z7L                                                               P63086               MK01_RAT                                        Rat                              plays important role in the MAPK/ERK cascade                                                                                       cytoplasm, nucleus
     41                        PRKACA PKACA                                                                             3AMB, 1SZM                                                         P17612 P00517    KAPCA_HUMAN KAPCA_BOVIN                           Human Bovine                          involved in the regulation of platelets                                                                                            cytoplasm. nucleus, cell membrane, mitochondria
     42                         ITK EMT LYK                                                                             3T9T, 3V8T                                                            Q08881               ITK_HUMAN                                      Human                             involved in regulation of the adaptive immune response                                                                             cytoplasm
     43                             MET                                                                                    3ZZE                                                               P08581               MET_HUMAN                                      Human                             mediates entry of the pathogen into cells                                                                                          membrane
     44                            CHK2                                                                                 2YCQ, 2YIT                                                            O96017              CHK2_HUMAN                                      Human                             required for checkpoint-mediated cell cycle arrest                                                                                 nucleus
     45                             TTK                                                                                    3HMO                                                               P33981               TTK_HUMAN                                      Human                             associated with cell proliferation                                                                                                 membrane, spindle
     46                            NTRK1                                                                                   4AOJ                                                               P04629              NTRK1_HUMAN                                     Human                             involved in the development and the maturation of the central and peripheral nervous systems                                       cell membrane, early endosome membrane, late endosome membrane
     47                             TTR                                                                                    1KGJ                                                               P02767               TTHY_RAT                                        Rat                              transports thyroxine from the bloodstream to the brain                                                                             secreted
     48                           HSD17B1                                                                                  3DHE                                                               P14061              DHB1_HUMAN                                      Human                             has 20-alpha-HSD activity                                                                                                          cytoplasm
     49                            METF                                                                                    3FSU                                                               P0AEZ1              METF_ECOLI                                    *E.coli*                            converts homocysteine to methionine                                                                                                cytosol
     50                           BETVIA                                                                                   4A84                                                               P15494              BEV1A_BETPN                               *Betula pendula*                        steroid carrier protein                                                                                                            cytoplasm

###### The list of characterized off-targets having significant binding efficiency towards gefitinib compared to their respective reported ligands.

  S. No.   Name                                           PDB    Ligand present in co**-**crystal   gefitinib MM-GBSA binding energy   known ligands MM-GBSA binding energy   ∆G~gef~/∆G~lig~   IC50 (nM) of known ligand
  -------- --------------------------------------------- ------ ---------------------------------- ---------------------------------- -------------------------------------- ----------------- ---------------------------
  1        Cyclin-dependent kinase 2                      2UZD                 C85                              −86.307                              −20.274                    4.257028707                ND
  2        Cyclin-dependent kinase 2                      2VTQ                 LZA                              −74.582                              −19.222                    3.880033295                ND
  3        Fibroblast growth factor receptor 2            3RI1                 3RH                              −77.977                              −28.889                    2.699193465                180
  4        Ephrin type-B receptor 4                       2×9F                 UNN                              −83.961                               −38.83                    2.16227144                 140
  5        STE20-like serine/threonine-protein kinase     2J51                 DKI                              −71.754                              −33.967                    2.112462096                140
  6        Mitogen-activated protein kinase 14            1WBW                 LI4                              −81.464                              −42.498                    1.916890207                 2
  7        HTH-type transcriptional regulator TtgR        2UXH                 QUE                              −100.838                             −55.277                    1.824230693                ND
  8        Serine/threonine-protein kinase pim-1          3MA3                 01I                               −89.67                              −50.377                    1.779978959                61
  9        Bone morphogenetic protein receptor type-1B    3MDY                 LDN                              −78.885                              −44.586                    1.769277352             5000 (Kd)
  10       Activin receptor type-1                        3MTF                 A3F                              −80.671                               −45.83                    1.760222562             614 (Kd)
  11       Mitogen-activated protein kinase 10            2O2U                 738                              −85.273                              −49.501                    1.722652068             400 (Ki)
  12       Cyclin-dependent kinase 2                      2IW6                 QQ2                              −80.586                               −51.35                    1.569347614               44000
  13       Insulin-like growth factor 1 receptor          2ZM3                 575                              −75.531                              −48.801                    1.547734678               22900
  14       Cyclin-dependent kinase 2                      2W17                 I19                              −79.496                               −51.79                    1.534968141                60
  15       Serine/threonine-protein kinase Chk1           2BRH                 DFW                               −70.09                              −45.808                    1.530082082                9.7
  16       Tyrosine-protein kinase ITK/TSK                3V8T                 477                              −83.127                              −54.685                    1.520106062                0.3

###### Binding energies of identified off-targets with gefitinib and their comparison with data previously reported in high throughput *in vitro* studies.

  -------- -------------------------------------------------------------- -------------------- ------------------------------------- ----------------------------------- ------------------- --------------------- -------------
  S. No.   Name                                                                Gene Name        mmGBSA DG binding energy (kcal/mol)   Anastassiadis et al. (% activity)   Davis et al. (Kd)   Apsel et al. (IC50)   ChEMBL (Ki)
  1        Mitogen-activated protein kinase10                                 MAPK10, JNK3                   −103.446                               96.64                       3200                  ---             794.33
  2        Serine/Threonine-protein kinase pim-1                                  PIM1                       −102.399                               86.45                        ---                  ---             1995.26
  3        Dihydroorotate dehydrogenase (quinone) mitochondrial                  DHODH                       −100.487                                ---                         ---                  ---               ---
  4        Receptor tyrosine-protein kinase erbB-4                            ERBB4, HER4                    −100.195                               24.15                        410                  ---             158.49
  5        Estradiol 17-beta-dehydrogenase 1                                    HSD17B1                       −97.635                                ---                         ---                  ---               ---
  6        Serine/Threonine-protein kinase Chk2                               CHEK2, CHK2                     −94.826                               83.95                        800                  ---             630.96
  7        Serine/Threonine-protein kinase Chk1                               CHEK1, CHK1                     −94.712                               95.27                        ---                  ---             6309.57
  8        Tyrosine-protein kinase Lck                                            LCK                         −93.312                               68.44                        630                  ---             398.11
  9        Hepatocyte growth factor receptor                                      MET                         92.659                                 ---                        3500                  ---               ---
  10       Mitogen activated protein kinase 14                                   MAPK14                       −91.953                               74.59                        ND                   ---             501.19
  11       tyrosine-protein kinase BTK                                            BTK                         −90.291                               60.56                        ---                  ---             1258.93
  12       Tyrosine-protein kinase ABL1                                        ABL1, JTK7                     −89.891                               86.35                        230                 1200               630
  13       Mitogen-activated protein kinase kinase kinase 9                   MAP3K9, MLK1                    −89.843                              109.52                        ---                  ---               ---
  14       Activin receptor type-1                                            ACVR1, ALK2                     −88.685                              105.63                        ---                  ---             3981.07
  15       Epidermal growth factor receptor                                 EGFR, ERBB, HER1                  −88.354                               2.97                          1                   ---               0.4
  16       High affinity nerve growth factor receptor                            NTRK1                        −87.784                                ---                         ---                  ---               ---
  17       Serine/Threonine-protein kinase 25                                    STK25                        −86.644                               97.38                        ---                  ---               ---
  18       proto-oncogene tyrosine protein kinase Src                             SRC                         −86.531                                79                         3800                 1100             1995.26
  19       Cyclin-dependent kinase 2                                          CDK2, CDKN2                     −86.307                              100.65                        ---                  ---             6309.57
  20       Serine/Threonine-protein kinase 17B                               STK17B, DRAK2                    −84.931                                ---                        3800                  ---               ---
  21       protein kinase C iota type                                            PRKCI                        −84.923                                ---                         ---                  ---             5011.87
  22       Ephrin type-B receptor 4                                         EPHB4, HTK, MYK1                  −83.961                               70.89                       2500                 1000                 
  23       Tyrosine-protein kinaseITK/TSK                                    ITK, EMT, LYK                    −83.127                               99.94                        ---                  ---               ---
  24       Myotonin protein kinase                                             DMPK, MDPK                     −81.558                               90.09                       6900                  ---               ---
  25       Serine/Threonine-protein kinase10                                   STK10, LOK                     −80.265                               38.59                        470                  ---               ---
  26       Aurora kinase A                                                 AURKA, STK15, STK6                 −74.879                               95.27                        ---                  ---             3162.28
  27       Bone morphogenetic protein receptor type-1B                           BMPR1B                       −78.885                                ---                         ---                  ---               ---
  28       Serine/Threonine-protein kinase receptor R3                        ACVRL1, ALK1                    −78.538                               96.86                        ---                  ---               ---
  29       ALK tyrosine kinase receptor                                           ALK                         −78.228                               98.75                        ---                  ---             1258.93
  30       Fibroblast growth factor receptor 2                                 FGFR2, BEK                     −77.977                               98.73                        ---                  ---               ---
  31       mitogen activated protein kinase 8                                 MAPK8, JNK1                     −77.826                               93.07                        ---                  ---               ---
  32       FIbroblast growth factor receptor 1                                   FGFR1                         −76.2                                96.4                          −                   ---             3981.07
  33       MAP kinase-activated protein kinase 2                                MAPKAPK2                      −75.845                               97.5                         ---                  ---                 
  34       Insulin-like growth factor 1 receptor                                 IGF1R                        −75.531                               92.33                        ---                  ---             1258.93
  35       Activated CDC42 kinase1                                             TNK2, ACK1                     −74.789                               72.8                         ---                  ---                 
  36       Mast/stem cell growth factor receptor Kit                           KIT, SCFR                      −73.003                               96.4                        1800                  ---               ---
  37       STE20-like serine/threonine-protein kinase                          SLK, STK2                      −71.754                               83.71                        920                  ---             398.11
  38       cAMP-dependent protein kinase catalytic subunit alpha             PRKACA, PKACA                    −69.932                                ---                         ---                  ---             5011.87
  39       Mitogen-activated protein kinase 1 (Rat; identical to Human)       MAPK1, ERK2                     −69.262                               103.1                        ---                  ---                 
  40       Tyrosine-protein kinase SYK                                            SYK                         −65.782                              104.18                        ---                  ---             1584.89
  41       Dual specificity protein kinase TTK                                    TTK                         −64.705                                                                                                     
  42       Cyclin-dependent kinase 6                                          CDK6, CDKN6                     −63.744                               98.69                        ---                  ---               ---
  -------- -------------------------------------------------------------- -------------------- ------------------------------------- ----------------------------------- ------------------- --------------------- -------------

[^1]: These authors jointly supervised this work.
